Annals of hepatology最新文献

{"title":"Nationwide analysis on the impact of the organization of care on the outcomes of perihilar cholangiocarcinoma.","authors":"Merve Rousian, Julien A Luyten, Lydia van der Geest, Stefan Buttner, Maxime Dewulf, Lydi M W J van Driel, Joris Erdmann, Dries Braat, Robert J Porte, Joanne Verheij, Judith de Vos-Geelen, Bas Groot Koerkamp, Pim B Olthof","doi":"10.1016/j.aohep.2026.102207","DOIUrl":"10.1016/j.aohep.2026.102207","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Perihilar cholangiocarcinoma (pCCA) is a rare and complex liver malignancy requiring specialized care in academic centers and multidisciplinary teams (MDTs). This study aimed to evaluate the impact of academic centers, academic MDTs, and regional collaboration on treatment outcomes.</p><p><strong>Materials and methods: </strong>Patients with pCCA between 2017 and 2021 were identified from the Dutch Cancer Registry. The impact of center of initial diagnosis, including academic and non-academic center, and the involvement of academic MDTs were analyzed. Outcomes included tumor-directed therapy and overall survival (OS).</p><p><strong>Results: </strong>In total, 1365 patients were included; 155 (11.4%) initially presented in an academic centers. Initial biliary drainage in academic centers was associated with lower 90-day mortality (25.0% and 40.5%, P < 0.001) compared with non-academic centers. Initial diagnosis in an academic center was associated with higher rates of tumor-directed therapy (63.5% vs 32.0%, P < 0.001) and surgery (36.1% vs 14.7%, P < 0.001). Expert MDT evaluation, regardless of center of diagnosis, showed higher rates of tumor-directed therapy (45.5% vs 9.9%, P < 0.001) and surgery (23.8% vs 2.5%, P < 0.001). Additionally, academic MDTs were independently associated with improved OS (HR 0.55 95% CI 0.48-0.63, P < 0.001) in multivariable analysis.</p><p><strong>Conclusions: </strong>Patients with pCCA discussed in academic MDTs had higher rates of tumor-directed therapy and improved OS. This association may partly be explained by patient selection and referral patterns. Nevertheless, these findings emphasize the importance of regional collaboration and centralization of care to ensure that all patients benefit from specialized expertise and coordinated treatment planning.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102207"},"PeriodicalIF":4.4,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147571786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming barriers to HCV screening in Latin America: From evidence to action.","authors":"Javier Crespo, Jose Luis Calleja, Ezequiel Ridruejo, Marta Alonso-Peña, Joaquín Cabezas, Graciela Elia Castro-Narro, Nelia Hernandez, Hugo Cheinquer, Fernando Contreras, Christie Perelló, Manuel Mendizabal, Fernando Cairo, Mário Guimarães Pessôa, Eduardo Emerim, Patricia Guerra Salazar, Rodrigo Zapata, Alejandro Soza, Leyla Maria Nazal Ortiz, Oscar A Beltran-Galvis, Javier Hernández-Blanco, Martin Garzón, Pablo Coste, Marianela Alvarado Salazar, Mirtha Infante-Velázquez, Enrique Carrera Estupiñán, Javier Mora, Marisabel Valdez, José Miguel Moreno, J Antonio Velarde-Ruiz Velasco, Tania Mayorga Marina, Miguel Antonio Mayo, Enrique Adames, Marcos Girala, Jorge Garavito-Rentería, Kriss Rodríguez Romero, Federico Rodríguez-Perez, Rocío Galloso Gentillea, Lucy Dagher, Victoria Mainardi","doi":"10.1016/j.aohep.2026.102189","DOIUrl":"10.1016/j.aohep.2026.102189","url":null,"abstract":"<p><p>Chronic hepatitis C virus (HCV) infection remains a major global public health challenge. Despite the availability of highly effective therapies capable of curing the vast majority of patients, millions remain undiagnosed and often present for medical care at advanced stages of disease. This delay not only increases mortality and the burden of cirrhosis and hepatocellular carcinoma but also affects quality of life, productivity, and healthcare system costs. In this context, screening emerges as a cornerstone for achieving HCV elimination. It enables the identification of hidden cases, early treatment initiation, prevention of complications, and reduction of community transmission. At the population level, prioritizing individuals with the highest likelihood of transmitting infection produces a multiplier effect, while both universal and risk-based strategies have consistently proven cost-effective, generating medium-term savings. In Latin America, the epidemiological landscape is heterogeneous. While overall prevalence in the general population is relatively low, high endemicity persists in vulnerable groups such as people who inject drugs, incarcerated individuals, and patients undergoing hemodialysis. Major barriers include fragmented health systems, lack of clinical registries, stigma, and restricted access to diagnosis and therapy. Yet, the region also holds clear opportunities: simplified diagnostic pathways using rapid testing and reflex algorithms, micro-elimination in key populations, pooled procurement of antivirals through the Pan American Health Organization, and the integration of digital health and telemedicine. In conclusion, HCV screening constitutes both a public health necessity and an ethical obligation. Its organized and sustainable implementation is essential to translate therapeutic efficacy into collective benefit and to accelerate progress toward the elimination of hepatitis C.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102189"},"PeriodicalIF":4.4,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of zinc in the gut-liver axis.","authors":"Kurt Grüngreiff, Dirk Reinhold, Wolfgang Maret","doi":"10.1016/j.aohep.2026.102188","DOIUrl":"10.1016/j.aohep.2026.102188","url":null,"abstract":"<p><p>The gut and the liver are the main organs in the regulation and distribution of zinc. Therefore, gut and liver disease impact zinc functions in other organs. Many of the phenomenological observations made in the past century concerning the role of zinc in growth and development and the role of zinc deficiency in many diseases are now better understood on the basis of zinc's remarkable catalytic, structural, and regulatory functions in over 3200 human proteins and its functions as an ionic messenger similar to calcium in intra- and extracellular communication, regulation of metabolism, and gene expression. Zinc has key roles in carbohydrate and lipid metabolism, nitrogen balance, pH control, and the synthesis and degradation of proteins. Its classification as a trace element distracts from its global significance in the proliferation and differentiation of all cells. Zinc is at least as important as iron, if not even more so. Its intricate cellular regulation by 24 membrane zinc transporters, a dozen metallothioneins and other zinc homeostatic proteins supports this tenet. This review will summarize the role of zinc in the integrity of the intestinal barrier, in maintaining a healthy gut, and, through the gut-liver axis, a healthy liver. Zinc is critical for a proper immune response to support and control inflammation, in fighting off insults and repairing tissues, but also in avoiding chronic inflammation. About 75% of patients with decompensated liver cirrhosis are zinc deficient. Zinc deficiency, a prooxidant and proinflammatory condition, needs clinical attention in liver disease, should include attention to gut health, and involve pharmacological treatment with supplemental zinc. Monotherapy with zinc alone, however, is not the answer. Along with zinc, additional therapeutics are required to restore intestinal and hepatic functions.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102188"},"PeriodicalIF":4.4,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146002962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening and management for portal hypertension in hepatocellular carcinoma: A nationwide survey in China.","authors":"Xueyan Li, Huiyu Chen, Qingqing Zhang, Shaotong Wang, Youping Wang, Yixuan Chen, Jun Song, Mingkai Chen","doi":"10.1016/j.aohep.2026.102184","DOIUrl":"10.1016/j.aohep.2026.102184","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Hepatocellular carcinoma (HCC) and portal hypertension (PHT) are two common complications of cirrhosis that often co-exist and significantly affect patient prognosis, yet global management varies widely. This study evaluated Chinese physicians' perspectives on PHT screening and management in HCC.</p><p><strong>Materials and methods: </strong>An online questionnaire survey was distributed to hepatologists, gastroenterologists, gastrointestinal oncologists, and hepatobiliary surgeons across 132 hospitals in 16 provinces throughout China from March 1, 2024, to June 30, 2024. The questionnaire comprised 57 items across four sections. This study was approved by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (No. 2024-0365) and registered at the Chinese Clinical Trial Registry (ChiCTR2400084630).</p><p><strong>Results: </strong>Overall, 1,584 participants responded to the questionnaire. The reported PHT screening rate in HCC patients was 82.6%. Imaging was the most common modality (50.5%), followed by endoscopy (30.8%). However, adherence to the Baveno VI/VII consensus was only 28%. Complications of PHT, including gastrointestinal bleeding and ascites, significantly affected physicians' screening practices. The primary and secondary prophylaxis strategies for PHT generally comply with the Baveno VII consensus. A history of acute variceal bleeding within 6 months significantly reduced the preference for atezolizumab and bevacizumab therapy (19.6% vs. 32.9%, P<0.001). In cases of acute variceal bleeding during atezolizumab-bevacizumab therapy, 79.5% of the physicians recommended permanent discontinuation of bevacizumab, whereas 20.5% advocated continuation upon achieving hemostasis.</p><p><strong>Conclusions: </strong>Substantial heterogeneity exists in the management of PHT among HCC patients in China, highlighting the need for targeted multidisciplinary education to standardize care and improve patient outcomes.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102184"},"PeriodicalIF":4.4,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Name MASLD/MASH - and act on it.","authors":"Jeffrey V Lazarus, Mário G Pessoa, Debbie L Shawcross, Peter Schwarz, Grace L Su, Simon Barquera","doi":"10.1016/j.aohep.2025.102171","DOIUrl":"https://doi.org/10.1016/j.aohep.2025.102171","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102171"},"PeriodicalIF":4.4,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145964814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma","authors":"Stephen Lam Chan ,&nbsp;Richard S. Finn ,&nbsp;Julien Edeline ,&nbsp;Sadahisa Ogasawara ,&nbsp;Jennifer J. Knox ,&nbsp;Bruno Daniele ,&nbsp;Baek-Yeol Ryoo ,&nbsp;Philippe Merle ,&nbsp;Mohamed Bouattour ,&nbsp;Ho-Yeong Lim ,&nbsp;Yee Chao ,&nbsp;Thomas Yau ,&nbsp;Barbara Anne Haber ,&nbsp;Usha Malhotra ,&nbsp;Abby B. Siegel ,&nbsp;Chih-Chin Liu ,&nbsp;Masatoshi Kudo ,&nbsp;Ann-Lii Cheng","doi":"10.1016/j.aohep.2025.102169","DOIUrl":"10.1016/j.aohep.2025.102169","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Prospective data are limited regarding viral hepatitis viral load and serology and immunotherapy in patients with hepatocellular carcinoma (HCC). This analysis evaluated hepatitis viral load and serology and transaminase levels in patients with sorafenib-treated advanced HCC who were receiving immunotherapy with pembrolizumab in the KEYNOTE-224 and KEYNOTE-240 studies.</div></div><div><h3>Materials and Methods</h3><div>This was a post hoc analysis of the single-arm phase II KEYNOTE-224 (NCT02702414) and the placebo-controlled phase III KEYNOTE-240 (NCT02702401) studies. Patients positive for hepatitis B surface antigen (HBsAg) and/or with detectable hepatitis B virus (HBV), patients positive for isolated total hepatitis B core antibody (anti-HBc), and patients currently or previously infected with hepatitis C virus (HCV) were included. Viral-induced hepatitis flare was defined as &gt;1 log increase from baseline and &gt;1000 IU/ml viral load with concurrent alanine aminotransferase (ALT) elevation classified according to prespecified thresholds.</div></div><div><h3>Results</h3><div>No patient in the pembrolizumab arm who was positive for HBsAg and/or with detectable HBV or who was positive for isolated anti-HBc met the criteria for viral-induced hepatitis flare; 1 patient (3.4%) in the placebo arm met the criteria for viral-induced hepatitis flare. One patient (2.3%) in the pembrolizumab arm of KEYNOTE-240 who was infected with HCV met the criteria for viral-induced hepatitis flare, but the event was not attributed to pembrolizumab.</div></div><div><h3>Conclusions</h3><div>These results suggest that pembrolizumab does not cause viral-induced hepatitis flare in patients with advanced HCC.</div></div><div><h3>ClinicalTrials.gov identifier</h3><div>NCT02702414 and NCT02702401.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"31 1","pages":"Article 102169"},"PeriodicalIF":4.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aspartate aminotransferase‑to‑platelet ratio index (APRI) reliably excludes advanced fibrosis and cirrhosis in treated autoimmune hepatitis","authors":"Martine A.M.C. Baven-Pronk ,&nbsp;Camiel J.M. Marijnissen ,&nbsp;Maaike Biewenga ,&nbsp;Albert F. Stättermayer ,&nbsp;Maarten E. Tushuizen ,&nbsp;Bart van Hoek","doi":"10.1016/j.aohep.2025.102146","DOIUrl":"10.1016/j.aohep.2025.102146","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Monitoring liver fibrosis during treatment of autoimmune hepatitis (AIH) is important to guide treatment. Transient elastography (TE) is not always available. Existing non-invasive fibrosis scores have been assessed primarily at diagnosis but not during treatment. This study aims to develop a non-invasive AIH fibrosis score (AIHFS) and validate its performance - alongside with existing fibrosis scores - for excluding advanced fibrosis (≥F3 on TE) and cirrhosis (F4 on TE) during AIH treatment.</div></div><div><h3>Patients and Methods</h3><div>This study included adult patients with AIH and variant syndromes from Leiden (derivation cohort, <em>n</em> = 73) and Vienna (validation cohort, <em>n</em> = 81). All patients had been treated for at least 6 months and had valid TE and routine laboratory tests within 1 months of TE. Existing fibrosis scores were calculated and a novel AIHFS was developed using multivariate regression. TE served as the reference standard.</div></div><div><h3>Results</h3><div>The aspartate aminotransferase-to-platelet ratio index (APRI) and AIHFS (comprising APRI and albumin) were the only fibrosis scores significantly associated with liver stiffness during treatment. AIHFS did not outperform APRI. APRI demonstrated a high negative predictive value for advanced fibrosis (≥F3 on TE) and cirrhosis (F4 on TE): 86 % and 93 % in the derivation cohort and 84 % and 95 % in the validation cohort, respectively. Based on an APRI threshold of 0.4874, only 22–40 % of patients would require further diagnostic assessment.</div></div><div><h3>Conclusions</h3><div>APRI is a simple, non-invasive, widely applicable score that reliably excludes advanced fibrosis (≥F3 on TE) and cirrhosis (F4 on TE) during AIH treatment, potentially reducing the need for additional investigations.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"31 1","pages":"Article 102146"},"PeriodicalIF":4.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reevaluating the clinical course of AMA-positive patients with normal liver enzymes: A large retrospective cohort study","authors":"Ahmad Yahia ,&nbsp;Fadi Abu Baker ,&nbsp;Mifleh Tatour ,&nbsp;Rawi Hazzan","doi":"10.1016/j.aohep.2025.102147","DOIUrl":"10.1016/j.aohep.2025.102147","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>The long-term clinical significance of anti-mitochondrial antibody (AMA)-positive patients with normal liver enzymes remains unclear. Despite increasing detection of AMA positivity in asymptomatic individuals, clinicians lack evidence-based protocols for long-term surveillance, and guidelines offer no clear recommendations. This study, the largest of its kind, investigates the natural history, prognostic implications, and risk factors for disease progression in this population.</div></div><div><h3>Materials and Methods</h3><div>We conducted a retrospective cohort study using a national healthcare database to identify adults (aged 18 years or older) with a positive AMA and normal alkaline phosphatase (ALP) levels between 2002 and 2023. Demographics, laboratory data, and liver-related outcomes were assessed. Multivariate logistic and Cox regression models were used to evaluate predictors of primary biliary cholangitis (PBC), cirrhosis, and hepatic complications.</div></div><div><h3>Results</h3><div>Among 1018 patients (median follow-up 6.3 years (IQR 2.5–11.5), 76 (7.5 %) developed PBC and 30 (2.9 %) progressed to cirrhosis. Liver-related complications were infrequent: esophageal varices (1.1 %), ascites (1.8 %), hepatocellular carcinoma (0.2 %), and liver transplantation (0.1 %). Higher AMA titers were strongly associated with increased risk of PBC, cirrhosis, and complications, showing a clear titer-dependent gradient. Longitudinal analysis also demonstrated titer-associated increases in ALP and bilirubin over time.</div></div><div><h3>Conclusions</h3><div>AMA-positive individuals with normal liver enzymes typically experience a benign clinical course. However, high AMA titers identify a subgroup at increased risk for progression to PBC and advanced liver disease. These findings underscore the importance of risk-stratified surveillance strategies in clinical practice, guiding healthcare professionals in the management of their patients.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"31 1","pages":"Article 102147"},"PeriodicalIF":4.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of cirrhotic cardiomyopathy in liver transplant candidates: Impact on pre- and post-transplant mortality","authors":"Ignacio Roca ,&nbsp;Cecilia Morales ,&nbsp;Mariela De Santos ,&nbsp;Nicolas Dominguez ,&nbsp;Luciana Meza ,&nbsp;Manuel Barbero ,&nbsp;Lucia Navarro ,&nbsp;Omar Galdame ,&nbsp;Mario Altieri ,&nbsp;Hongqun Liu ,&nbsp;Samuel S. Lee ,&nbsp;Fernando Cairo ,&nbsp;Graciela Reyes","doi":"10.1016/j.aohep.2025.102141","DOIUrl":"10.1016/j.aohep.2025.102141","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Cirrhotic cardiomyopathy (CCM) is defined as the presence of cardiac dysfunction in patients with cirrhosis in the absence of pre-existing heart disease. Reported prevalence thus far has varied between 17.5% and 35%, depending on the studies. In 2020, diagnostic criteria were revised based on imaging advances. The aim of this study was to evaluate the prevalence of CCM and its impact on overall mortality on the waiting list and post-transplantation.</div></div><div><h3>Materials and Methods</h3><div>A prospectively recorded database was retrospectively analyzed. Consecutive adult patients who were evaluated and placed on the waiting list for liver transplantation (LT) from 2019 to 2023 were enrolled. Survival curves for patients with and without cirrhotic cardiomyopathy were constructed using the Kaplan-Meier method, and differences were compared by the Log-rank test. Multiple regression analysis was performed by the Cox proportional hazards model.</div></div><div><h3>Results</h3><div>A total of 451 patients were assessed, of whom 389 (86.3%) met inclusion criteria. The median age was 55 years (IQR 46–61) with 236 (60.7%) males. The most common etiology of cirrhosis was hepatitis C, 110/389 (28.3%). The prevalence of CCM was 16.2% (63/389). Thirty-seven patients (9.5%) met systolic criteria, and 27 (6.9%) met diastolic criteria for CCM. No mean differences were found in MELD-Na (15, IQR 11–19, vs 14, IQR 10–16.5, <em>p</em>00.1) or decompensations. The presence of hepatocellular carcinoma was higher in the CCM group (44.4% vs. 22.1% <em>p</em> &lt; 0.01).The median overall survival time on the waitlist was longer in the group without CCM compared to that in the CCM group (32 vs 22 months, <em>p</em> = 0.04). In Cox regression analysis, the presence of CCM (HR 1.71 CI95% 1.09–2.68 <em>p</em>00.02), HCC (HR 2.37, CI95% 1.47–3.82 <em>p</em> &lt; 0.001) and higher MELD-Na (HR 1.14 CI95% 1.10–1.18, <em>p</em> &lt; 0.001) were predictors of mortality on the waiting list. There were no significant differences in survival between the groups post-transplantation.</div></div><div><h3>Conclusions</h3><div>Our study revealed a lower prevalence of CCM in liver transplant candidates compared with previous reports. Moreover, it underscores that CCM was an independent predictor of mortality on a liver transplantation waitlist, highlighting its significant clinical implications. Further research is imperative to elucidate its precise impact on post-transplant survival.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"31 1","pages":"Article 102141"},"PeriodicalIF":4.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145311947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH”","authors":"Qianxin Lou,&nbsp;Xuxia Chu","doi":"10.1016/j.aohep.2026.102208","DOIUrl":"10.1016/j.aohep.2026.102208","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"31 1","pages":"Article 102208"},"PeriodicalIF":4.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147615709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}